Could a spice compound ease diabetic nerve pain?
NCT ID NCT07313111
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding thymoquinone, a compound from black seed oil, to the standard pain drug pregabalin could better relieve nerve pain in people with diabetes. Fifty adults with diabetic peripheral neuropathy took both treatments daily for two months. Researchers measured pain levels, nerve function, and markers of inflammation and oxidative stress to see if the combination offered extra benefit.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- thymoquinone (a compound from black seed oil) and pregabalin
- What this could lead to
- If it works, this could point toward a simple supplement-based way to boost pain relief and nerve health for people with diabetic neuropathy.
- What could go wrong
- This is a small, completed phase 4 trial with only 50 participants. Results may not apply to everyone, and the supplement's long-term safety or benefit is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
50 people
The number who actually took part.
- Started
-
Jul 2024
- Finished
-
Sep 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Both males or females of any race over 18 years of age. 2. Patients with either type1 or type2 diabetes, who have been on a stable anti-diabetic medication regimen for at least 30 days before randomization. 3. Duration of painful diabetic peripheral neuropathy was required to be more than 3 months. Exclusion Criteria: 1. History of smoking, alcohol consumption, and thyroid gland disorder. 2. Patients with any kidney disorder or any conditions that could confound the assessment of pain due to diabetic peripheral neuropathy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetic peripheral neuropathy (DPN) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hawler medical university, Galyawa diabetic center and Neurophysiology department of hawler psychiatric hospital
Erbil, IRAQ, 44001, Iraq
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ancient herbal remedy put to the test against Diabetes' nerve damage
- Can a vitamin b derivative beat standard b vitamins for diabetic nerve pain?
- New ultrasound and blood test could spot diabetic nerve damage sooner
- Can simple foot exercises prevent falls in diabetics?
- Could a daily 5-Minute mask soothe nerve pain?
- Can acupuncture needles zap away diabetic nerve pain?